Patients with germline BRCA mutations who were diagnosed with breast cancer at or before age 40 and who underwent a bilateral risk-reducing mastectomy (RRM) and/or a risk-reducing salpingo-oophorectomy (RRSO) had lower rates of recurrence, secondary breast and/or ovarian malignancies, and death than those who did not undergo these surgeries,...
American Association for Cancer Research Dec 11 2024 Patients with germline BRCA mutations who were diagnosed with breast cancer at or before age 40 and who underwent a bilateral risk-reducing mastectomy and/or a risk-reducing salpingo-oophorectomy had lower rates of recurrence, secondary breast and/or ovarian malignancies, and death than those who did not undergo these surgeries, according to results presented at the San Antonio Breast Cancer Symposium , held December 10-13, 2024.
To study the association between RRM and/or RRSO and survival outcomes, Lambertini and colleagues conducted an analysis of the BRCA BCY Collaboration study, an international, multicenter, retrospective cohort study of patients with germline pathogenic or likely pathogenic variants of BRCA who were diagnosed with stage 1-3 breast cancer at the age of 40 or younger between January 2000 and December 2020.
Specifically, patients who had a RRM had a 35% lower risk of death and a 42% lower risk of breast cancer recurrence or a second primary malignancy. The improved outcomes were observed regardless of whether the germline BRCA mutation was present in the BRCA1 or BRCA2 gene. This global study provides the first evidence that risk-reducing surgeries improve survival outcomes among young BRCA-mutation carriers with a prior history of early-onset breast cancer. We believe that our findings are critical for improving the counseling of BRCA-mutation carriers with early-onset breast cancer on cancer-risk management strategies."
Cancer Mutation Surgery Gene Germline Hormone Hospital Infertility Mastectomy Menopause Oncology Oophorectomy Research
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Olaparib provides survival benefits for high-risk BRCA-positive breast cancer patientsPatients with high-risk, BRCA-positive breast cancer who received olaparib (Lynparza) after standard treatment continued to have better survival outcomes than those who received placebo after a median follow-up of 6.
Read more »
New risk score identifies heart disease risk in kidney transplant patientsUsing an innovative risk score assessment score, heart researchers at Intermountain Health in Salt Lake City say they can accurately predict whether patients being assessed for kidney transplant will likely have a future major cardiac event, like a heart attack or stroke, according to a new study.
Read more »
Wearables and machine learning predict five-year fall risk in Parkinson’s patientsWearable sensor data combined with machine learning predicts fall risk in Parkinson's patients, enhancing preventive care and clinical outcomes over five years.
Read more »
Antibody trials show encouraging results in patients with high-risk forms of two blood cancersTwo clinical trials testing the antibody loncastuximab tesirine (Zynlonta) showed encouraging results in patients with high-risk forms of two blood cancers – follicular lymphoma and marginal zone lymphoma.
Read more »
Common heart failure drug reduces risk of chemotherapy-induced heart damage in cancer patientsA commonly prescribed medication for heart failure was linked to a lower risk of heart damage, or cardiotoxicity, among high-risk cancer patients undergoing chemotherapy treatment using anthracyclines, according to preliminary late-breaking science presented today at the American Heart Association's Scientific Sessions 2024.
Read more »
NSAIDs raise bleeding risk in patients taking blood thinnersPeople who take an anticoagulant medicine double their risk of an internal bleed if they take a type of painkiller called a non-steroidal anti-inflammatory drug (NSAID) such as ibuprofen, diclofenac or naproxen, according to research published in the European Heart Journal [1] today (Monday).
Read more »